Moderna to Initiate P-III Study of its mRNA-1273 Against COVID-19 in July 2020

 Moderna to Initiate P-III Study of its mRNA-1273 Against COVID-19 in July 2020

Moderna to Initiate P-III Study of its mRNA-1273 Against COVID-19 in July 2020

Shots:

  • The P-III study will evaluate mRNA-1273 vs PBO in a ratio (1:1) and is expected to enroll ~30,000 patients in the US, to be conducted in collaboration with NIAID. The 1EP of P-III study will be the prevention of symptomatic COVID-19 while 2EP include prevention of severe COVID-19
  • The company has finalized 100 μg as a P-III dose based on the results of P-I study. Moderna will deliver ~500M doses/ year or may ramp up to ~1B doses/ year under a manufacturing agreement with Lonza and is expected to be initiated in 2021
  • BARDA has supported the planning for the P-II and P-III studies of mRNA-1273 as well as the manufacturing scale-up of mRNA-1273. In P-II study, the company has completed the r enrollment of younger adults (n=300) and the sentinel group of older adults (n=50)

Click here to read full press release/ article | Ref: Moderna | Image: Forbes

Related News: Moderna Signs a Ten-Year Worldwide Agreement with Lonza to Manufacture mRNA-1273 Against COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post